BiomX Inc. (PHGE): Price and Financial Metrics


BiomX Inc. (PHGE): $0.73

-0.04 (-5.14%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PHGE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PHGE Stock Price Chart Interactive Chart >

Price chart for PHGE

PHGE Price/Volume Stats

Current price $0.73 52-week high $6.73
Prev. close $0.76 52-week low $0.64
Day low $0.69 Volume 43,300
Day high $0.78 Avg. volume 28,329
50-day MA $1.34 Dividend yield N/A
200-day MA $2.01 Market Cap 21.59M

BiomX Inc. (PHGE) Company Bio


BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.


PHGE Latest News Stream


Event/Time News Detail
Loading, please wait...

PHGE Latest Social Stream


Loading social stream, please wait...

View Full PHGE Social Stream

Latest PHGE News From Around the Web

Below are the latest news stories about BiomX Inc that investors may wish to consider to help them evaluate PHGE as an investment opportunity.

BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation

BRANFORD, Conn. & NESS ZIONA, Israel, January 04, 2022--BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will receive a Therapeutics Development Award of up to $5 million from the Cystic Fibrosis Foundation ("CF Foundation").

Yahoo | January 4, 2022

BiomX (PHGE) Investor Presentation - Slideshow

No summary available.

Seeking Alpha | November 19, 2021

BiomX (NYSEMKT:PHGE) Lowered to Hold at Zacks Investment Research

Zacks Investment Research cut shares of BiomX (NYSEMKT:PHGE) from a buy rating to a hold rating in a research note released on Wednesday morning, Zacks.com reports. According to Zacks, BiomX Ltd is a clinical stage microbiome company. It engages in developing both natural and engineered phage cocktails designed to target and destroy bacteria which affect []

Transcript Daily | November 18, 2021

Zacks Investment Research Lowers BiomX (NYSEMKT:PHGE) to Hold

Zacks Investment Research lowered shares of BiomX (NYSEMKT:PHGE) from a buy rating to a hold rating in a report published on Wednesday, Zacks.com reports. According to Zacks, BiomX Ltd is a clinical stage microbiome company. It engages in developing both natural and engineered phage cocktails designed to target and destroy bacteria which affect the appearance []

Dakota Financial News | November 18, 2021

BiomX Presenting at Two Upcoming Conferences in November

Jefferies London Healthcare Conference on November 18 - 19, 2021 2021 Phage Futures Congress Europe on November 23 - 24, 2021 NESS ZIONA, Israel, Nov. 17, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced upcoming presentations at the Jefferies London Healthcare Conference on November 18-19 and the 2021 Phage Futu

Yahoo | November 17, 2021

Read More 'PHGE' Stories Here

PHGE Price Returns

1-mo -49.66%
3-mo -48.95%
6-mo -63.68%
1-year -87.89%
3-year N/A
5-year N/A
YTD -54.38%
2021 -74.92%
2020 -34.12%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7679 seconds.